Qlaris Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
770 Legacy Pl Fl 2, Dedham, Massachusett...Website
qlaris.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Qlaris Bio
Qlaris Bio is a clinical-stage biotechnology company dedicated to developing innovative first-in-class therapies aimed at treating serious ophthalmic diseases, particularly glaucoma. Their lead product, QLS-111, targets intraocular pressure through a unique mechanism of action, offering potential advantages over existing treatments. The company focuses on addressing significant unmet needs in ophthalmology, including conditions like Primary Open-Angle Glaucoma and Ocular Hypertension. Qlaris Bio's commitment is to preserve vision and prevent blindness for patients suffering from debilitating eye conditions.Explore more
Qlaris Bio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Qlaris Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Qlaris Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Qlaris Bio
Funding: Get notified immidiatlly once Qlaris Bio has new funding data
Product Launch: Get notified when Qlaris Bio launches new products
Check if Qlaris Bio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Qlaris Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Qlaris Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Qlaris Bio had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Qlaris Bio
Compare insights from companies similar to Qlaris Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Qlaris Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Qlaris Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Qlaris Bio.
Qlaris Bio financials insights
Gather financial insights about Qlaris Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series B
$24M
2026
Debt
$3.9M
Qlaris Bio Tech Stack
A closer look at the technologies used by Qlaris Bio
Most Recent Scoops
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Qlaris Bio News & Media
Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congress
DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of its lead investigational compound QLS-111 will be presented at the 2025 World Glaucoma Congress (WGC). This will include an oral presentation on clinical data from the recently completed QC-111-201 “Osprey” and QC-111-203 “Apteryx” Phase 2 studies in patients with primary open-angle glaucoma (POAG) aQlaris Bio Announces Positive Topline Data From Two Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials investigating QLS-111 in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). The Phase II trials (Osprey and Apteryx) successfully met all primary and secondary endpoints. Qlaris Bio will present a corporate update at the Glaucoma 360 New HoriQlaris raises $24 million for development of IOP-lowering therapy - Healio
Qlaris Bio raised $24 million during series B financing for the clinical development of QLS-111, a new IOP-lowering drug candidate for patients with glaucoma, the company announced in a press release.The financing was co-led by Canaan and New Leaf Venture Partners, and included abrdn Inc., Mayo Clinic Ventures and Correlation Ventures as well.Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma
DEDHAM, Mass.--(BUSINESS WIRE)-- #EVP--Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. Co-led by Canaan and New Leaf Venture Partners, the financing also included new participation from funds managed by abrdn Inc., as well as existing investors Mayo Clinic Ventures and Correlation Ventures. Proceeds from the financing will support the continued
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Qlaris Bio
Sign Up For FreeTo access detailed company insights
Qlaris Bio is a clinical-stage biotechnology company dedicated to developing innovative first-in-class therapies aimed at treating serious ophthalmic diseases, particularly glaucoma. Their lead product, QLS-111, targets intraocular pressure through a unique mechanism of action, offering potential advantages over existing treatments. The company foc... Read More
